| Systematic (IUPAC) name | |
|---|---|
| O3-[1-[di(phenyl)methyl]azetidin-3-yl] O5-propan-2-yl 2-amino-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate | |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Pregnancy cat. | ? |
| Legal status | ℞ Prescription only |
| Routes | Oral |
| Identifiers | |
| CAS number | 123524-52-7 |
| ATC code | None |
| PubChem | CID 65948 |
| ChemSpider | 59352 |
| UNII | PV23P19YUG |
| KEGG | D01145 |
| Chemical data | |
| Formula | C33H34N4O6 |
| Mol. mass | 582.64 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| |
|
Azelnidipine (INN; marketed under the brand name Calblock) is a dihydropyridine calcium channel blocker. It is sold in Japan by Daiichi-Sankyo pharmaceuticals, Inc. Unlike nicardipine, it has a gradual onset and has a long-lasting hypotensive effect, with little increase in heart rate.[1]
| This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)